Veracyte Inc. (VCYT) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Veracyte Inc. (VCYT:NASDAQ), powered by AI.

Current Price
$50.92
P/E Ratio
60.3
Market Cap
4.0B
Sector
Healthcare
What is the Veracyte Inc. stock price forecast?

Veracyte Inc. is currently trading at $50.92. View real-time AI analysis on Alpha Lenz.

What is Veracyte Inc. insider trading activity?

View the latest insider trading data for Veracyte Inc. on Alpha Lenz.

What is Veracyte Inc.'s P/E ratio?

Veracyte Inc.'s P/E ratio is 60.3.

Veracyte Inc.

NASDAQ · VCYT
$50.92+1.77(+3.60%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Veracyte Inc.'s future dividend policy...
Alpha Chat Insight

Veracyte Inc. trades at a P/E of 60.3 (premium valuation) with modest ROE of 5.3%. 3Y revenue CAGR of 20.4% highlights clear growth momentum.

Ask for details

Company Overview

Veracyte Inc. is a genomic diagnostics company specializing in advanced molecular diagnostic tests that address critical healthcare needs. The primary function of Veracyte is to improve patient outcomes by providing more precise and less invasive diagnosis through genomic testing. This enables physicians to make better-informed treatment decisions, particularly in oncology, pulmonology, and other critical medical areas. Notable features of Veracyte's offerings include tests that reduce the need for unnecessary surgeries and procedures by providing reliable diagnostic results, thereby impacting the healthcare system by minimizing patient risk and overall healthcare costs. The company's products are largely based on proprietary genomic platforms and algorithms, driving their innovation in diagnostic accuracy. In the financial markets, Veracyte plays an essential role by offering investors exposure to the rapidly evolving field of precision medicine and genomic diagnostics. Its contributions to the healthcare sector underscore the growing demand for personalized medical solutions, reflecting broader trends towards value-based care and technological advancements in medical diagnostics.

CEOMr. Marc A. Stapley
SectorHealthcare
IndustryDiagnostics & Research
Employees824

Company Statistics

FY 2025

Profile

$4.00BMarket Cap
$517.14MRevenue
0.00Shares Out
824Employees

Margins

70.10%Gross
21.82%EBITDA
15.14%Operating
13.19%Pre-Tax
12.83%Net

Valuation

60.31P/E
3.06P/B
7.74EV/Sales
32.60EV/EBITDA
31.60P/FCF

Growth (CAGR)

20.37%Rev 3Yr
34.50%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

4.90%ROA
5.34%ROE
5.04%ROIC

Financial Health

$362.58MCash & Cash Equivalents
$-266.13MNet Debt
7.36%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Veracyte Inc. (ticker: VCYT) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 824 employees. Market cap is $4.0B.

The current price is $50.92 with a P/E ratio of 60.31x and P/B of 3.06x.

ROE is 5.34% and operating margin is 15.14%. Annual revenue is $517M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Veracyte Inc. (VCYT) Stock Forecast 2026 $50.92 — Price, Financials & Analyst Targets | Alpha Lenz